138 related articles for article (PubMed ID: 25575344)
1. The heterogeneity of concentrated prescribing behavior: Theory and evidence from antipsychotics.
Berndt ER; Gibbons RS; Kolotilin A; Taub AL
J Health Econ; 2015 Mar; 40():26-39. PubMed ID: 25575344
[TBL] [Abstract][Full Text] [Related]
2. Patient, Physician and Organizational Influences on Variation in Antipsychotic Prescribing Behavior.
Tang Y; Chang CC; Lave JR; Gellad WF; Huskamp HA; Donohue JM
J Ment Health Policy Econ; 2016 Mar; 19(1):45-59. PubMed ID: 27084793
[TBL] [Abstract][Full Text] [Related]
3. Medical decision making in antipsychotic drug choice for schizophrenia.
Hamann J; Langer B; Leucht S; Busch R; Kissling W
Am J Psychiatry; 2004 Jul; 161(7):1301-4. PubMed ID: 15229068
[TBL] [Abstract][Full Text] [Related]
4. A population-based study of antipsychotic prescription trends in children and adolescents in British Columbia, from 1996 to 2011.
Ronsley R; Scott D; Warburton WP; Hamdi RD; Louie DC; Davidson J; Panagiotopoulos C
Can J Psychiatry; 2013 Jun; 58(6):361-9. PubMed ID: 23768264
[TBL] [Abstract][Full Text] [Related]
5. Patterns of Antipsychotic Prescribing by Physicians to Young Children.
Huskamp HA; Horvitz-Lennon M; Berndt ER; Normand ST; Donohue JM
Psychiatr Serv; 2016 Dec; 67(12):1307-1314. PubMed ID: 27417891
[TBL] [Abstract][Full Text] [Related]
6. Changes in physician antipsychotic prescribing preferences, 2002-2007.
Donohue J; O'Malley AJ; Horvitz-Lennon M; Taub AL; Berndt ER; Huskamp HA
Psychiatr Serv; 2014 Mar; 65(3):315-22. PubMed ID: 24337224
[TBL] [Abstract][Full Text] [Related]
7. The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state.
Berkowitz RL; Patel U; Ni Q; Parks JJ; Docherty JP
J Clin Psychiatry; 2012 Apr; 73(4):498-503. PubMed ID: 22226332
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic prescribing: do conflict of interest policies make a difference?
Anderson TS; Huskamp HA; Epstein AJ; Barry CL; Men A; Berndt ER; Horvitz-Lennon M; Normand SL; Donohue JM
Med Care; 2015 Apr; 53(4):338-45. PubMed ID: 25769055
[TBL] [Abstract][Full Text] [Related]
9. Regional Variation in Physician Adoption of Antipsychotics: Impact on US Medicare Expenditures.
Donohue JM; Normand SL; Horvitz-Lennon M; Men A; Berndt ER; Huskamp HA
J Ment Health Policy Econ; 2016 Jun; 19(2):69-78. PubMed ID: 27453458
[TBL] [Abstract][Full Text] [Related]
10. Variation in long-term antipsychotic polypharmacy and high-dose prescribing across physicians and hospitals.
Latimer EA; Naidu A; Moodie EE; Clark RE; Malla AK; Tamblyn R; Wynant W
Psychiatr Serv; 2014 Oct; 65(10):1210-7. PubMed ID: 24981557
[TBL] [Abstract][Full Text] [Related]
11. How quickly do physicians adopt new drugs? The case of second-generation antipsychotics.
Huskamp HA; O'Malley AJ; Horvitz-Lennon M; Taub AL; Berndt ER; Donohue JM
Psychiatr Serv; 2013 Apr; 64(4):324-30. PubMed ID: 23280376
[TBL] [Abstract][Full Text] [Related]
12. Effects of Physician-directed Pharmaceutical Promotion on Prescription Behaviors: Longitudinal Evidence.
Datta A; Dave D
Health Econ; 2017 Apr; 26(4):450-468. PubMed ID: 26893065
[TBL] [Abstract][Full Text] [Related]
13. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
[TBL] [Abstract][Full Text] [Related]
14. Space-Time Cluster Analysis to Detect Innovative Clinical Practices: A Case Study of Aripiprazole in the Department of Veterans Affairs.
Penfold RB; Burgess JF; Lee AF; Li M; Miller CJ; Nealon Seibert M; Semla TP; Mohr DC; Kazis LE; Bauer MS
Health Serv Res; 2018 Feb; 53(1):214-235. PubMed ID: 28004385
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Young People With Antipsychotic Medications in the United States.
Olfson M; King M; Schoenbaum M
JAMA Psychiatry; 2015 Sep; 72(9):867-74. PubMed ID: 26132724
[TBL] [Abstract][Full Text] [Related]
16. Prescription preferences in antipsychotics and attitude towards the pharmaceutical industry in Belgium.
Cleymans S; Morrens M; Bervoets C
J Med Ethics; 2017 Jun; 43(6):359-363. PubMed ID: 27895084
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic treatment of adults in the United States.
Olfson M; King M; Schoenbaum M
J Clin Psychiatry; 2015 Oct; 76(10):1346-53. PubMed ID: 26528641
[TBL] [Abstract][Full Text] [Related]
18. Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics.
Samalin L; Garnier M; Auclair C; Llorca PM
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869767
[TBL] [Abstract][Full Text] [Related]
19. Evolution of First-generation and Second-generation Antipsychotic Prescribing Patterns in Belgium Between 1997 and 2012: A Population-based Study.
Morrens M; Destoop M; Cleymans S; VAN DER Spek S; Dom G
J Psychiatr Pract; 2015 Jul; 21(4):248-58. PubMed ID: 26164050
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of diabetes and antipsychotic prescription patterns in patients with schizophrenia: a nationwide retrospective cohort study.
Okumura Y; Ito H; Kobayashi M; Mayahara K; Matsumoto Y; Hirakawa J
Schizophr Res; 2010 Jun; 119(1-3):145-52. PubMed ID: 20304611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
